Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of sFOLFOXIRI in Advanced Gastroesophageal Cancer (SAGE)

NCT05332002 is registered in ClinicalTrials.gov with Rutgers, The State University of New Jersey as lead sponsor.

NCT NCT05332002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05332002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of sFOLFOXIRI in Advanced Gastroesophageal Cancer (SAGE)
Lead sponsor
Rutgers, The State University of New Jersey
Phase
Phase 2
Overall status
Recruiting
Start date
July 13, 2022
Completion date
August 1, 2027
Enrollment
38 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

gastro-intestinal cancer